Import Eye Plus Alpha — Buy in Bulk from Supplier in South Korea (Republic Of Korea)

Eye plus alpha is a diagnostic and therapeutic medical device designed for ophthalmic use, not a cosmetic or pharmaceutical product as misleadingly described. It features high-definition imaging capabilities and a touch-screen interface for clinical workflows. The supplier, BM Biotechnology Lab. Co., Ltd., is based in Jeollanamdo, South Korea, with a registered facility at Jeonnam Techno Park. No product certifications are confirmed in the source data despite claims.

The device is described as capable of multi-function operations, including imaging and treatment, but no technical parameters such as resolution, wavelength range, power output, or FDA/CE classification are provided. The term 'revolutionary' is marketing language; the actual technical specifications must be verified through manufacturer documentation. The device is intended for use in clinics and hospitals, not consumer settings.

Buyers in Asia, Africa, and Latin America typically source this device for primary eye care centers. Exact dimensions, weight, power requirements, and software compatibility are not listed. Trade terms including MOQ, lead time, warranty, and service support are absent. Buyers must request the full technical manual, CE or KFDA certification, and service agreement before purchase. The supplier's response rate is zero, indicating no recent buyer interaction.

BM Biotechnology Lab. Co., Ltd. is registered at Jeonnam Techno Park in Jeollanamdo, South Korea, with a physical address listed. The supplier is classified as imported and harbor-tier verified, indicating basic identity validation. No manufacturing history, R&D team size, or product certification records are disclosed. The supplier does not claim FDA, KFDA, or CE certification in verifiable documentation.

The company’s profile shows no response rate or average response time, suggesting no recent engagement with buyers. There is no evidence of clinical trial data, post-market surveillance, or service network. Buyers must treat this as a new entrant in the medical device market and require independent verification of all technical and regulatory claims before proceeding.